Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 4/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14045371 | 1.00 | NPSR1 (0.53) | NPSR1ALDH1A1TDP1MMP13FFAR1 | |
| SCHEMBL14045407 | 0.92 | TDP1 (0.48) | NPSR1ALDH1A1TDP1MMP13F2 | |
| SCHEMBL4609773 | 0.92 | TDP1 (0.48) | NPSR1ALDH1A1TDP1MMP13F2 | |
| SCHEMBL4597080 | 0.91 | MMP13 (0.49) | NPSR1ALDH1A1TDP1MMP13F2 | |
| SCHEMBL14045372 | 0.91 | MMP13 (0.49) | NPSR1ALDH1A1TDP1MMP13F2 | |
| SCHEMBL14045373 | 0.91 | NPSR1 (0.56) | NPSR1ALDH1A1TDP1MMP13F2 | |
| SCHEMBL4597319 | 0.91 | NPSR1 (0.56) | NPSR1ALDH1A1TDP1MMP13F2 | |
| SCHEMBL4608942 | 0.87 | MMP13 (0.46) | NPSR1ALDH1A1TDP1MMP13F2 | |
| SCHEMBL14131144 | 0.87 | MMP13 (0.46) | NPSR1ALDH1A1TDP1MMP13F2 | |
| SCHEMBL4597749 | 0.85 | TDP1 (0.54) | TDP1MMP13F2MMP9CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2008-07-24 | — | — | US | claimed |
| US-7399786-B2 | Derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. (US) | 2008-07-15 | — | — | US | claimed |
| WO-2007005774-A9 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS INC (US) | 2007-03-08 | — | — | WO | claimed |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | claimed |
| US-20080261981-A1 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2008-07-24 | — | — | US | disclosed |
| US-7399786-B2 | Derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1907352-A2 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | Bexel Pharmaceuticals Inc (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007005774-A9 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS INC (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007005774-A2 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | BEXEL PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | BEXEL PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175795-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | GPR119, AADAT, FABP4 | NPSR1 1249/4885ALDH1A1 3132/4885TDP1 3135/4885 |
| US-20070004725-A1 | Novel derivatives of amino acids for treatment of obesity and related disorders | GPR119, AADAT, FABP4 | NPSR1 1249/4885ALDH1A1 3132/4885TDP1 3135/4885 |
| US-20080261981-A1 | NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS | GPR119, AADAT, FABP4 | NPSR1 1249/4885ALDH1A1 3132/4885TDP1 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.